Xanodyne Pharmaceuticals (XANO) Files $86M IPO
More News related to IPOs
- GM's Chairman Says Focus Is On Paying Back Government, Not an IPO - WSJ
- Golden Green (CHOP) Announces 4.8M Common Offering at $5/Share
Xanodyne Pharmaceuticals (Nasdaq: XANO) filed a registration statement with the SEC for an initial public offering of its common stock. The proposed maximum aggregate offering price is $86.25 million. The company plans to list on the NASDAQ under the stock symbol "XANO."
The offering is being made through Morgan Stanley, Deutsche Bank Securities, RBC Capital Markets and Natixis Bleichroeder Inc.
Xanodyne Pharmaceuticals is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women’s healthcare and pain management. Xanodyne markets a portfolio of revenue generating products and is advancing a late stage pipeline of product candidates targeted at significant potential markets in its focus areas.
Stocks Mentioned
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
